Anticoagulation Management for Spine Procedures

Risk Stratification Framework

Anticoagulation management for spine procedures is based on a risk stratification system that categorizes procedures by their proximity to the neuraxis and the consequences of bleeding.

SIS Procedure Risk Categories

Low-Risk (Peripheral) Procedures:

• Medial branch blocks
• SI joint injections
• Peripheral nerve blocks
• Trigger point injections
• Peripheral joint injections
• Peripheral RFA

Intermediate-Risk Procedures:

• Transforaminal epidural injections
• Facet joint injections

High-Risk (Neuraxial) Procedures:

• Interlaminar epidural injections
• Cervical epidural injections
• Spinal cord stimulator placement/revision
• Intrathecal pump procedures
• Adhesiolysis procedures
• Facet cyst rupture (due to epidural communication)

IPSIS Three-Tier Bleeding Risk Classification

The IPSIS technical manual further organizes bleeding risk into a detailed procedure-specific table:

Intermediate-High Bleeding Risk:

• All interlaminar epidurals (cervical, thoracic, lumbar)
• Caudal epidurals
• SCS lead placement
• Vertebral augmentation and basivertebral nerve RFN

Presumed Low-Intermediate Bleeding Risk (insufficient data):

• Cervical and thoracic TFESI
• Lumbosacral TFESI
• Cervical medial branch RFN
• Cervical and thoracic disc access/stimulation

Low Bleeding Risk:

• Lumbar and cervical MBBs and facet injections
• Lumbar medial branch RFN
• SIJ injections and sacral lateral branch blocks/RFN
• Lumbar disc access

Medication-Specific Guidance

For LOW-RISK/PERIPHERAL Procedures

| Medication | Recommendation | |-----------|----------------| | Aspirin (81 or 325 mg) | Continue | | Clopidogrel (Plavix) | Generally continue | | Warfarin | Generally continue if INR therapeutic | | DOACs (apixaban, rivaroxaban) | Generally continue or hold for shortest interval | | Enoxaparin | Generally continue or hold single dose |

Key message: Do NOT hold anticoagulation for peripheral procedures.

For INTERMEDIATE Procedures (TFESI, Facet Injections)

| Medication | Recommendation | |-----------|----------------| | Aspirin | Continue | | Clopidogrel | Practice varies; many experts continue | | Warfarin | Some hold; others continue if INR <3 | | DOACs | Practice varies; some hold 24-48 hours |

This is the area of greatest practice variability.

For HIGH-RISK/NEURAXIAL Procedures

| Medication | Recommendation | |-----------|----------------| | Low-dose aspirin (81 mg) | Generally continue | | Therapeutic aspirin | Consider holding | | Clopidogrel | Hold 5-7 days (per ASRA) | | Warfarin | Hold 5 days; confirm INR <1.5 | | DOACs | Hold 2-5 half-lives depending on agent and renal function | | Enoxaparin | Hold 12-24 hours (prophylactic vs therapeutic dosing) |

SSRIs and NSAIDs: Special Considerations (IPSIS)

SSRIs may impair platelet function through their effect on serotonin reuptake in platelets. The absolute bleeding risk is low, so SSRIs do not routinely need to be held for spine procedures. However, if clinical bleeding risk is elevated, the prescribing physician should participate in shared decision-making.

NSAIDs vary in their effect on platelet function. Nonselective NSAIDs (ibuprofen, naproxen, diclofenac, indomethacin) inhibit COX-1 and impair platelet aggregation more significantly than COX-2-selective agents. Celecoxib is the only COX-2-selective NSAID with multiple studies confirming no additional procedural bleeding risk compared to placebo. Given the elective nature of spine procedures, physicians should weigh the risks and benefits of continuing NSAIDs on a case-by-case basis.

Bleeding Diathesis Screening (IPSIS)

Patients with inherited or acquired coagulopathies require special attention. Key screening indicators include spontaneous bruising, bleeding gums, nosebleeds, hemarthrosis, menorrhagia, or excessive bleeding after prior dental/surgical procedures. Von Willebrand disease is the most common inherited platelet disorder, and desmopressin (DDAVP) may be used prophylactically before procedures when indicated by hematology.

For patients with known bleeding diathesis, the IPSIS manual recommends hematology consultation. Platelet infusions or thrombopoietin receptor agonists can be considered before higher-risk procedures. A platelet count threshold of 50 x 10^9/L is commonly used as an absolute cutoff for lumbar puncture or epidural access.

Practical Needle Technique to Reduce Bleeding Risk (IPSIS)

The IPSIS manual highlights several technique-related strategies to minimize hemorrhagic complications during procedures where anticoagulation is continued:

• Use a 25-gauge spinal needle for transforaminal injections to minimize vascular trauma
• Limit the number of needle adjustments within the intervertebral foramen
• Perform careful real-time fluoroscopic observation during contrast injection to detect vascular uptake before delivering therapeutic medications
• For medications with standardized assays (e.g., INR for warfarin), verify levels before the procedure regardless of whether the drug is being continued or has been held

UpToDate Risk-Benefit Framework for Anticoagulation Management

UpToDate provides a complementary framework for managing anticoagulation in the setting of interventional pain procedures:

Core Principles:

• Patients on anticoagulant or antiplatelet medications, or those with severe thrombocytopenia, face increased procedural bleeding risk
• The degree of risk and consequences of bleeding depend on the procedure site and whether bleeding can be identified and compressed
• Decisions about temporarily stopping anticoagulants should be individualized, requiring a risk-benefit analysis that incorporates the reason the patient is anticoagulated
• These decisions often require collaboration among three parties: the interventionalist, the referring clinician, and the patient

Pain Society Guidelines on Procedure Risk Tiers (UpToDate):

• Pain medicine societies have developed guidelines assigning bleeding risk levels to various interventional procedures
• These guidelines include specific timing recommendations for when to perform procedures relative to doses of medications affecting coagulation
• For low-risk procedures (e.g., medial branch blocks, peripheral nerve blocks), it may be unnecessary to stop anticoagulants or antiplatelets, or to time the procedure around medication doses
• For high-risk neuraxial procedures, anticoagulation is occasionally modified or held several days before the procedure
• RFA is contraindicated in patients with active infection, but anticoagulation is not an absolute contraindication — medications are occasionally modified or held based on the specific procedure

Timing Recommendations:

• UpToDate references society guideline tables with specific timing intervals for each anticoagulant relative to procedure risk tier
• The approach should factor in the ability to compress the bleeding site post-procedure — peripheral soft tissue sites carry much less risk than confined neuraxial spaces
• Coagulopathy is listed as a strict contraindication for epidural glucocorticoid injection, reinforcing that neuraxial access requires normal hemostasis

The Critical Principle

The decision to hold anticoagulation must balance:

• Risk of procedural bleeding (which varies by procedure type)
• Risk of thromboembolic event from holding (stroke, MI, PE, DVT)

For peripheral procedures, the thromboembolic risk almost always exceeds the bleeding risk. For neuraxial procedures, the catastrophic consequences of epidural hematoma (paralysis) justify holding.